Point72 Asset Management
NMRA icon

Point72 Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Point72 Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,500,000
Closed -$15.9M – 2367
2024
Q4 		$15.9M Buy
+1,500,000
New +$18M 0.04% 540

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Point72 Asset Management's NMRA Position: Q1 2026 in Review

Point72 Asset Management reduced its Neumora Therapeutics (NMRA) stake by 84% in Q1 2026, selling an estimated $7.96M and leaving 602,403 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Point72 Asset Management first reported a position in NMRA in Q3 2024 and has held it in 3 quarters since. The position peaked at $6.58M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Point72 Asset Management held 602,403 shares of Neumora Therapeutics worth $1.17M as of Q1 2026.
  • Point72 Asset Management sold 3,071,436 Neumora Therapeutics shares in Q1 2026, an estimated $7.96M.
  • Neumora Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2665 holding.
  • Point72 Asset Management first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Point72 Asset Management's Neumora Therapeutics position peaked at $6.58M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.